Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer stem cell marker expression and methylation status in patients with colorectal cancer.
Mersakova S, Janikova K, Kalman M, Marcinek J, Grendar M, Vojtko M, Kycina R, Pindura M, Janik J, Mikolajcik P, Gabonova E, Laca L, Mejstrikova E, Halasova E, Strnadel J, Lasabova Z. Mersakova S, et al. Among authors: mejstrikova e. Oncol Lett. 2022 May 27;24(1):231. doi: 10.3892/ol.2022.13352. eCollection 2022 Jul. Oncol Lett. 2022. PMID: 35720495 Free PMC article.
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcova P, Janikova A, Markova J, Obr A, Berkova A, Kubinyi J, Vaskova M, Mejstrikova E, Campr V, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M. Klener P, et al. Among authors: mejstrikova e. Hematol Oncol. 2018 Feb;36(1):110-115. doi: 10.1002/hon.2483. Epub 2017 Oct 30. Hematol Oncol. 2018. PMID: 29083050
Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
Klener P, Fronkova E, Kalinova M, Belada D, Forsterova K, Pytlik R, Blahovcova P, Simkovic M, Salek D, Mocikova H, Prochazka V, Janikova A, Vaskova M, Mejstrikova E, Kodet R, Trka J, Trneny M. Klener P, et al. Among authors: mejstrikova e. Hematol Oncol. 2018 Dec;36(5):773-778. doi: 10.1002/hon.2550. Epub 2018 Sep 13. Hematol Oncol. 2018. PMID: 30129045 Clinical Trial.
The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.
Bornhauser B, Cario G, Rinaldi A, Risch T, Rodriguez Martinez V, Schütte M, Warnatz HJ, Scheidegger N, Mirkowska P, Temperli M, Möller C, Schumich A, Dworzak M, Attarbaschi A, Brüggemann M, Ritgen M, Mejstrikova E, Hofmann A, Buldini B, Scarparo P, Basso G, Maglia O, Gaipa G, Skoblyn TL, Te Kronnie G, Vendramini E, Panzer-Grümayer R, Barz MJ, Marovca B, Hauri-Hohl M, Niggli F, Eckert C, Schrappe M, Stanulla M, Zimmermann M, Wollscheid B, Yaspo ML, Bourquin JP. Bornhauser B, et al. Among authors: mejstrikova e. Blood Adv. 2020 Sep 8;4(17):4052-4064. doi: 10.1182/bloodadvances.2019000938. Blood Adv. 2020. PMID: 32853382 Free PMC article.
92 results